Xbiotech INC 8-K filings

XBiotech Inc. announced the retirement of CEO John Simard, effective December 8, 2025, with Chief Scientific Officer Sushma Shivaswamy appointed as interim CEO.

XBiotech Inc. filed an amended 8-K to clarify director Craig Rademaker's role as a consultant to Canadian private equity firms, focusing on capital markets.

XBiotech Inc. entered into a new Executive Employment Agreement with CEO John Simard, formalizing his compensation and outlining terms for his continued leadership and potential departure.

XBiotech Inc. stockholders approved all Board of Directors' recommendations at their annual meeting on August 29, 2025, including the election of five directors and the 2025 Equity Incentive Plan.

XBiotech Inc. announced the immediate appointments of Dr. Thomas Kündig and Craig Rademaker to its Board of Directors, enhancing its scientific and financial expertise.

XBiotech Inc. notifies NASDAQ of director W. Thorpe McKenzie's retirement and its plan to address Audit and Compensation Committee vacancies to maintain compliance with listing rules.

W. Thorpe McKenzie retires from XBiotech's Board of Directors, effective immediately, after serving since 2009.

XBiotech Inc. has appointed Dr. Tak W. Mak, a world-renowned scientist, to its Board of Directors, filling an existing vacancy.

XBiotech Inc. successfully held its annual stockholders meeting on June 20, 2024, electing five directors and ratifying its independent auditor.